In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni appoint new executives, secure new partnerships, raise new funding, receive FDA Breakthrough Designation, and much more on the road to LSI Europe ‘24 in Sintra, Portugal (Sept 16-20).
Appointed Joseph Doyle, a long-term advisor for CereGate, as CFO. CereGate is a brain-computer interface company developing a neural interface system that writes information directly into the brain. CereGate’s therapeutic solution aims to improve the quality of life for individuals with neurological disorders or sensory deficits.
Received Breakthrough Device Designation from the U.S. FDA for its eShuntⓇ System, which is intended to treat normal pressure hydrocephalus. CereVasc is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for individuals with neurological diseases.
Appointed Tim Hopper, an entrepreneurial medical device industry leader, as CEO. Cerulean Scientific is developing and commercializing a new category of implantable, indwelling medical devices that resist clogging, obstructions, and biofouling.
Appointed Christian Howell, a recognized healthcare leader, as CEO. Cognito Therapeutics is developing a novel, non-invasive neuromodulation therapy to treat neurodegenerative diseases. Cognito’s therapy is designed to evoke specific brain wave activity with the goal of preserving brain structure, cognition, and function.
Secured $5.8M in Seed funding. eXeX is an AI and mixed reality software company that is creating a platform that allows surgical teams to onboard staff and complete surgical procedures with enhanced efficiency and accuracy. The funds will be used to accelerate the platform’s development and support its upcoming commercial debut.
Announced a $4.2M additional funding round. Hexoskin develops smart clothing with embedded biometric sensors to monitor vital signs. The funds will be used to invest in growth, digital biomarker research, and new AI-based digital diagnostic solutions.
Announced a strategic partnership with Tribun Health Partners, a digital pathology company. Ibex is a leader in the AI-powered cancer diagnostics space. Under the terms of the agreement, Tribun Health will offer Ibex’s product line as part of its CaloPixⓇ IMS platform.
Announced $10.75M in Series A funding and the launch of an IDE trial aimed at improving clinical outcomes for women undergoing breast reconstruction after surgery. The Absorbable Antibacterial Soft Tissue Support in Breast Reconstruction with Infectious Outcomes (ARIA) clinical trial is a multicenter, nationwide, randomized, control study evaluating the safety and efficacy of the Melody Matrix™, Melodi’s antibacterial soft tissue support device.
Received a new investment from Zynext Ventures, the Venture Capital arm of Zydus Lifesciences. Neuro42 is developing and commercializing advanced portable MRI technology and image-guided interventions for neurological diseases and conditions.
Appointed Heather Gervais, Osso VR’s previous CRO, as CEO. Osso VR offers a VR-based surgical training and assessment platform designed to improve the confidence and proficiency of healthcare companies and professionals. The platform allows healthcare professionals to practice and refine their skills in a risk-free digital environment.
Appointed medical device executive Liam Burns as CEO. Qaelon Medical is developing the first platform that combines real-time detection of life-threatening surgical leaks with surgical insufflation. Qaelon’s patented system builds upon existing insufflation technology but is enhanced with proprietary controls, digital sensors, software, and data algorithms.
Announced the successful initiation of its first-in-human study of its SonoThrombectomy™ system to treat individuals with venous thromboembolism. The SonoThrombectomy™ system is a pharmacomechanical ultrasound-facilitated thrombolytic-enhanced thrombectomy system that uses microbubble-mediated cavitation as the primary mechanism of action to remove blood clots more effectively.
Announced the issuing of two HCPCS codes by the CMS. These codes cover Sparrow AscentⓇ, the first FDA-cleared, non-invasive neurostimulation device that delivers transcutaneous auricular neurostimulation (tANⓇ) therapy for opioid withdrawal treatment.
Received a CE marking for its automated blood-drawing device. Vitestro’s device uses a combination of AI-based ultrasound-guided imaging and robotic needle insertion to automate the blood-drawing process.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
